Ascendis Pharma Q3 2023 Gaap EPS $(3.13) Misses $(2.75) Estimate, Sales $52.28M Miss $52.70M Estimate
Portfolio Pulse from saritha@benzinga.com
Ascendis Pharma (NASDAQ:ASND) reported Q3 2023 losses of $(3.13) per share, missing the analyst consensus estimate of $(2.75) by 13.82%. This is a 2.62% decrease over losses from the same period last year. The company also reported quarterly sales of $52.28 million, missing the analyst consensus estimate of $52.70 million by 0.79%. However, this is a 239.19% increase over sales from the same period last year.
November 07, 2023 | 9:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ascendis Pharma's Q3 2023 earnings missed estimates with a loss per share of $(3.13) and sales of $52.28 million. However, sales increased by 239.19% compared to the same period last year.
Ascendis Pharma's earnings miss could negatively impact the stock price in the short term as it indicates the company's performance was below market expectations. However, the significant YoY sales increase might mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100